2021
DOI: 10.20944/preprints202111.0050.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Review of Pre-clinical Studies

Abstract: Currently, there are no pharmacological treatments able to reverse nigral degeneration in Parkinson’s disease (PD), hence the unmet need for the provision of neuroprotective agents. Cannabis-derived phytocannabinoids (CDCs) and resveratrol (RSV) may be useful neuroprotective agents for PD due to their anti-oxidative and anti-inflammatory properties. To evaluate this, we undertook a systematic review of the scientific literature to assess the neuroprotective effects of CDCs and RSV treatments in pre-c… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 9 publications
(1 citation statement)
references
References 74 publications
(279 reference statements)
0
1
0
Order By: Relevance
“…Neuroprotective properties of cannabinoids have also been suggested via elevated CB 2 expression in microglial cells within the substantia nigra of humans and animal models of PD [28]. A systematic review of Cannabis-derived phytocannabinoids in PD preclinical models demonstrated neuroprotective effects evidenced by increased dopamine levels and prolonged dopaminergic neuronal survival [29].…”
Section: Preclinical Evidencementioning
confidence: 99%
“…Neuroprotective properties of cannabinoids have also been suggested via elevated CB 2 expression in microglial cells within the substantia nigra of humans and animal models of PD [28]. A systematic review of Cannabis-derived phytocannabinoids in PD preclinical models demonstrated neuroprotective effects evidenced by increased dopamine levels and prolonged dopaminergic neuronal survival [29].…”
Section: Preclinical Evidencementioning
confidence: 99%